Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry

Blood (2023) 141 (6): 659–672.

https://doi.org/10.1182/blood.2022016660

Published: 2023

Includes: Supplemental data

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Precision Co-Targeting of the Thymic Stromal Lymphopoietin Receptor in Childhood CRLF2 -Rearranged Acute Lymphoblastic Leukemia

Asen Bagashev, Joseph Patrick Loftus, Savannah Ross, Lisa M Niswander, Haiying Qin, Terry J. Fry, Sarah K Tasian

Blood (2021) 138 (Supplement 1): 1705.

https://doi.org/10.1182/blood-2021-148602

Published: 2021

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Liora M Schultz, MD, Kara L. Davis, DO, Christina Baggott, RN, PhD, Christie Chaudry, NP, Anne Cunniffe Marcy, MSBH, Sharon Mavroukakis, Bita Sahaf, PhD, Katherine A Kong, Lori S Muffly, MD, Stephen Kim, Everett H Meyer, MD PhD, Terry J. Fry, MD, Haiying Qin, MS, David B. Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 898.

https://doi.org/10.1182/blood-2018-99-117445

Published: 2018

Journal Articles

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Nasheed Hossain, MD, Bita Sahaf, PhD, Matthew Abramian, PhD, Jay Y. Spiegel, MD, Katie Kong, Stephen Kim, Sharon Mavroukakis, Jean Oak, MD PhD, Yasodha Natkunam, MD PhD, Everett H Meyer, MD PhD, Matthew J. Frank, MD PhD, Steven A Feldman, PhD, Steven R. Long, MD, Haiying Qin, MS, Terry J. Fry, MD, Lori S Muffly, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 490.

https://doi.org/10.1182/blood-2018-99-110142

Published: 2018

Journal Articles

Murine pre–B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor

Haiying Qin, Kazusa Ishii, Sang Nguyen, Paul P. Su, Chad R. Burk, Bong-Hyun Kim, Brynn B. Duncan, Samikasha Tarun, Nirali N. Shah, M. Eric Kohler, Terry J. Fry

Blood (2018) 132 (18): 1899–1910.

https://doi.org/10.1182/blood-2017-12-815548

Published: 2018

Includes: Supplemental data

Journal Articles

Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22 lo B-Lineage Leukemia and Lymphoma

Sneha Ramakrishna, MD, Sang M Nguyen, BS, Haiying Qin, MS, Steven L Highfill, PhD, Ira Kraft, John Shern, MD, Zachary Walsh, Dimiter Dimitrov, PhD, Terry J Fry, MD

Blood (2017) 130 (Supplement 1): 3894.

https://doi.org/10.1182/blood.V130.Suppl_1.3894.3894

Published: 2017

Journal Articles

Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19 + CD22 + , CD19 - , and CD22 - Pre-B Leukemia

Haiying Qin, MS, Sang M Nguyen, BS, Sneha Ramakrishna, MD, Samiksha Tarun, MSc, Lila Yang, BS, Nicholas Peter Verdini, BS, Waleed Haso, MS, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 810.

https://doi.org/10.1182/blood.V130.Suppl_1.810.810

Published: 2017

Journal Articles

Direct Comparison of Anti-CD33 and Anti-CD123 Chimeric Antigen Receptor T Cells with CD28 or 41BB Co-Stimulatory Domains for Treatment of Acute Myeloid Leukemia

Samiksha Tarun, MSc, Haiying Qin, MS, Lila Yang, BS, Christopher Daniel Chien, PhD, Mark Eric Kohler, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1370.

https://doi.org/10.1182/blood.V130.Suppl_1.1370.1370

Published: 2017

Journal Articles

Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy

Haneen Shalabi, DO, Haiying Qin, MS, Kelsey Wanhainen, BS, Jillian Smith, BS, Rimas Orentas, PhD, Nirali N Shah, MD, Shannon L Maude, MD PhD, Sarah K Tasian, MD, David T Teachey, MD, Javed Khan, MD, Terry J Fry, MD

Blood (2016) 128 (22): 4019.

https://doi.org/10.1182/blood.V128.22.4019.4019

Published: 2016

Journal Articles

Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies

Marianna Sabatino, Jinhui Hu, Michele Sommariva, Sanjivan Gautam, Vicki Fellowes, James D. Hocker, Sean Dougherty, Haiying Qin, Christopher A. Klebanoff, Terry J. Fry, Ronald E. Gress, James N. Kochenderfer, David F. Stroncek, Yun Ji, Luca Gattinoni

Blood (2016) 128 (4): 519–528.

https://doi.org/10.1182/blood-2015-11-683847

Published: 2016

Includes: Supplemental data

Journal Articles

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

Elad Jacoby, Yinmeng Yang, Haiying Qin, Christopher D. Chien, James N. Kochenderfer, Terry J. Fry

Blood (2016) 127 (10): 1361–1370.

https://doi.org/10.1182/blood-2015-08-664250

Published: 2016

Includes: Supplemental data

Journal Articles

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Yinmeng Yang, BS, Tasha Lin, MD, Elad Jacoby, MD, Haiying Qin, MS, Elizabeth Grier Gardner, MD, Christopher Daniel Chien, PhD, Daniel W. Lee, III, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 100.

https://doi.org/10.1182/blood.V126.23.100.100

Published: 2015

Journal Articles

Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR

Elad Jacoby, MD, Sang Minh Nguyen, BS, Kathryn M Welp, Haiying Qin, MS, Yinmeng Yang, BS, Christopher Daniel Chien, PhD, John Shern, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 2524.

https://doi.org/10.1182/blood.V126.23.2524.2524

Published: 2015

Journal Articles

Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22

Haiying Qin, MS, Waleed Haso, MS, Sang Minh Nguyen, BS, Terry J Fry, MD

Blood (2015) 126 (23): 4427.

https://doi.org/10.1182/blood.V126.23.4427.4427

Published: 2015

Journal Articles

CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells

Christopher Daniel Chien, PhD, Sang Minh Nguyen, BS, Haiying Qin, MS, Elad Jacoby, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 1432.

https://doi.org/10.1182/blood.V126.23.1432.1432

Published: 2015

Journal Articles

Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein

Haiying Qin, Monica Cho, Waleed Haso, Ling Zhang, Sarah K. Tasian, Htoo Zarni Oo, Gian Luca Negri, Yongshun Lin, Jizhong Zou, Barbara S. Mallon, Shannon Maude, David T. Teachey, David M. Barrett, Rimas J. Orentas, Mads Daugaard, Poul H. B. Sorensen, Stephan A. Grupp, Terry J. Fry

Blood (2015) 126 (5): 629–639.

https://doi.org/10.1182/blood-2014-11-612903

Published: 2015

Includes: Supplemental data

Journal Articles

Presence of Endogenous TCR Antigen in Vivo Attenuates Efficacy of Anti-CD19 Targeted CAR T Cell Therapy

Yinmeng Yang, BS, Christopher Daniel Chien, PhD, Elad Jacoby, MD, Haiying Qin, MS, Waleed Haso, MS, Terry J Fry, MD

Blood (2014) 124 (21): 3721.

https://doi.org/10.1182/blood.V124.21.3721.3721

Published: 2014

Journal Articles

CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia

Elad Jacoby, MD, Haiying Qin, MS, Yinmeng Yang, BS, Christopher Daniel Chien, PhD, Terry J Fry, MD

Blood (2014) 124 (21): 1115.

https://doi.org/10.1182/blood.V124.21.1115.1115

Published: 2014

NARROW

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Precision Co-Targeting of the Thymic Stromal Lymphopoietin Receptor in Childhood CRLF2 -Rearranged Acute Lymphoblastic Leukemia

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Murine pre–B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor

Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22 lo B-Lineage Leukemia and Lymphoma

Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19 + CD22 + , CD19 - , and CD22 - Pre-B Leukemia

Direct Comparison of Anti-CD33 and Anti-CD123 Chimeric Antigen Receptor T Cells with CD28 or 41BB Co-Stimulatory Domains for Treatment of Acute Myeloid Leukemia

Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy

Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR

Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22

CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells

Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein

Presence of Endogenous TCR Antigen in Vivo Attenuates Efficacy of Anti-CD19 Targeted CAR T Cell Therapy

CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only